Want to see IXHL full AI Analyst Report?
IXHL Stock Chart & Stats
$2.95
$0.09(3.05%)
At close: 4:00 PM EDT
$2.95
$0.09(3.05%)
Day’s Range― - ―
52-Week Range$2.49 - $27.69
Previous CloseN/A
Volume29.18K
Average Volume (3M)229.06K
Market Cap
$35.18M
Enterprise Value-$30.07M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta3.68
Next Earnings
Sep 02, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding11,964,554
10 Day Avg. Volume132,145
30 Day Avg. Volume229,058
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.85
Enterprise Value/Revenue-451.35
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$18.00Price Target Upside510.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$40.00M
Bulls Say, Bears Say
Bulls Say
Clinical Advancement Of Lead Asset IHL-42XCommencing active Phase 2 screening materially de-risks development timing and data generation for IHL-42X. Durable impact: it advances regulatory interactions under FDA Fast Track, creates a clearer Phase III pathway, and strengthens the case for partnerships or licensing ahead of commercialization.
Strengthened U.S. Intellectual PropertyA key U.S. patent through 2040 provides a multi-year exclusivity window that supports long-term commercial economics for IHL-42X. Durable impact: strengthens competitive moat, enhances deal-making leverage, and supports pricing and market-entry planning if clinical success is achieved.
Material Non-dilutive R&D Funding ReceivedSignificant non-dilutive receipts extend cash runway without equity dilution, directly funding clinical programs. Durable impact: improves near-term financial resilience, allows advancement of IHL-42X and other assets with less reliance on immediate equity raises, and can support strategic partnering.
Bears Say
Persistent Negative Operating And Free Cash FlowSustained cash burn forces ongoing external financing or asset monetization to fund trials. Durable impact: constrains management flexibility, increases dilution or debt risk over time, and creates execution risk if future funding or milestone payments fall short of expectations.
Heavy Net Losses And Weak MarginsConsistent, sizeable losses erode capital efficiency and delay path to positive returns. Durable impact: reduces ability to self-fund commercialization, pressures ROE long-term, and magnifies dependence on successful clinical milestones to translate R&D into sustainable revenue.
Clinical-stage Model With Limited Commercial RevenueAs a predominantly clinical-stage company, revenue generation hinges on trial success, approvals, or licensing. Durable impact: long timelines and binary clinical outcomes amplify funding needs and execution risk, making near-term operations sensitive to development progress rather than recurring sales.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.49 and its highest was $27.69 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $35.18M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 30 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Undervalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate is -0.14.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 11,964,554 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (510.17% Upside)
$18.00 (510.17% Upside)
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
395.67%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
IXHL Stock 12 Month Forecast
Average Price Target
$18.00
▲(510.17% Upside)
Technical Analysis
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―